BEIJING LUZHU BIOTECHNOLOGY CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.75 HKD | -0.72% |
|
-0.89% | -7.19% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 1.14M 158K 1.24M | Sales 2025 * | 100M 13.89M 109M | Capitalization | 5.18B 718M 5.62B |
|---|---|---|---|---|---|
| Net income 2024 * | -326M -45.17M -353M | Net income 2025 * | -336M -46.55M -364M | EV / Sales 2024 * | 4,109 x |
| Net cash position 2024 * | 499M 69.14M 541M | Net cash position 2025 * | 264M 36.58M 286M | EV / Sales 2025 * | 49.1 x |
| P/E ratio 2024 * |
-15.9
x | P/E ratio 2025 * |
-15.4
x | Employees | 133 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 8.67% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.72% | ||
| 1 week | -0.18% | ||
| Current month | -0.89% | ||
| 1 month | +47.45% | ||
| 3 months | -1.42% | ||
| 6 months | -18.86% | ||
| Current year | -7.19% |
1 week
26.00
28.20
1 month
18.0028.30
Current year
17.0031.95
1 year
16.1442.00
3 years
16.1442.00
5 years
16.1442.00
10 years
16.1442.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Kong
CEO | Chief Executive Officer | 61 | 01-12-31 |
Hui Zhang
DFI | Director of Finance/CFO | 56 | - |
Ling Peng
CHM | Chairman | 43 | 18-12-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Biao Ma
BRD | Director/Board Member | 60 | 19-08-25 |
Ai Jun Hou
BRD | Director/Board Member | 58 | - |
Yan Ping Zhang
BRD | Director/Board Member | - | 13-06-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 27.75 | -0.72% | 1,800 |
| 24-05-06 | 27.95 | +3.52% | 7,200 |
| 24-05-03 | 27 | -3.57% | 9,800 |
| 24-05-02 | 28 | 0.00% | 9,200 |
| 24-04-30 | 28 | +0.72% | 1,600 |
Delayed Quote Hong Kong S.E., May 07, 2024 at 04:08 am EDT
More quotes
Beijing Luzhu Biotechnology Co Ltd is a China-based company principally engaged in drug discovery, research and development and commercialization. The Company is also engaged in out-licensing human vaccines and therapeutic biologics. Its products under clinical development include recombinant herpes zoster vaccine LZ901, and antibody injection products K3 and K193. Its LZ901 is mainly used to prevent herpes zoster caused by varicella zoster virus in adults aged 50 and above. The Company operates in the domestic market and overseas markets.
Sector
Pharmaceuticals
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
25.6
CNY
Average target price
27.73
CNY
Spread / Average Target
+8.30%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.19% | 724M | |
| -2.47% | 88.14B | |
| +3.29% | 40.44B | |
| -15.40% | 32.24B | |
| +51.96% | 24.39B | |
| -14.35% | 15.59B | |
| -39.65% | 12.3B | |
| -6.52% | 12.18B | |
| -13.41% | 12.14B | |
| +5.17% | 8.87B |
- Stock Market
- Equities
- 2480 Stock